Skip to content

Control of Iatrogenic Endobronchial Bleeding by Tranexamic Acid, Adrenalin and Hemagglutinase

Control of Iatrogenic Endobronchial Bleeding by Tranexamic Acid,Adrenalin and Hemagglutinase: a Double-blind Randomized Controlled Trial

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06149091
Enrollment
300
Registered
2023-11-28
Start date
2023-12-01
Completion date
2024-12-31
Last updated
2023-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iatrogenic Endobronchial Bleeding

Keywords

flexible bronchoscopy, diagnostic flexible bronchoscopy, hemocoagulase, Tranexamic Acid, Adrenalin

Brief summary

A prospective national multi-center study will be conducted to evaluate the effectiveness of hemocoagulase in iatrogenic airway bleeding in a large class III hospital, such as the Second Affiliated Hospital of Harbin Medical University, the First Affiliated Hospital of Nanchang University, and to compare it with topical epinephrine and tranexamic acid in a prospective double-blind cluster randomized controlled trial.

Interventions

DRUGTranexamic Acid;

Tranexamic acid (TXA) is an antifibrinolytic drug that competitively inhibits the activation of plasminogen. After its efficacy and safety were confirmed in several randomized controlled trials, both systemic and topical administration of TXA have been widely used for hemostasis in trauma and various surgical settings.

In diagnostic bronchoscopy, one of the most commonly used topical hemostatic agent is epinephrine. The primary mechanism of epinephrine is vasoconstriction, leading to reduced blood flow and hemostasis.

DRUGHemagglutinase

Thrombin injection (Batroxobin) is an enzymatic hemostatic agent refined from the venom of the Brazilian lancehead snake. It promotes clot formation at the bleeding site, characterized by rapid and effective hemostasis and high safety. It is now widely used for clinical prevention and treatment of perioperative bleeding and oozing. Multiple randomized controlled studies have evaluated the safety and efficacy of intravenous/topical application of thrombin in various trauma and surgical settings.

Sponsors

The Second Affiliated Hospital of Harbin Medical University
CollaboratorOTHER
The First Affiliated Hospital of Nanchang University
CollaboratorOTHER
China-Japan Friendship Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* During diagnostic bronchoscopy, patients with bronchial bleeding that was not successfully controlled with cold (4°C) saline (3 times within 60 seconds, 5ml each time).

Exclusion criteria

* 1: Patients with contraindications for diagnostic flexible bronchoscopy. 2: Coagulopathy (PV INR \>1.3). 3: Thrombocytopenia (\<50x10\^9) or anemia (hgb \<80 g/L). 4: Direct oral anticoagulant, low molecular weight heparin, or antiplatelet therapy. 5: Thrombophilia, history of pulmonary embolism or deep vein thrombosis. 6: Contraindications for the use of epinephrine in the bronchus. 7: Coronary artery disease, cerebrovascular disease, history of rapid arrhythmias. 8: Uncontrolled pulmonary hypertension. 9: Cardiovascular decompensation. 10: Severe hypoxia (PaO2 \<60mmHg, SaO2 \<90%, FiO2 \>=60%).

Design outcomes

Primary

MeasureTime frameDescription
Intratracheal bleeding control rateUp to a single examination, no more than 1 minute after each drug application. Under bronchoscopy, physicians visually assess clot formation to evaluate bleeding controlThe percentage of iatrogenic bronchial bleeding successfully controlled in each group (%)

Secondary

MeasureTime frameDescription
Number of tranexamic acid/adrenaline/thrombin applications required to control bronchial bleedingUntil the end of a single procedure (bronchoscopy), up to 1 minute after each drug application.Number of tranexamic acid/adrenaline/thrombin applications required to control bronchial bleeding
Number of recurrent bleeding episodes after infusion of tranexamic acid/adrenaline/thrombin (N)Within 24 hours after a single procedure (bronchoscopy)Number of recurrent bleeding episodes after infusion of tranexamic acid/adrenaline/thrombin (N)
Percentage (%) of iatrogenic bronchial bleeding successfully controlled in each group in relation to the severity of the bleeding.Up to the end of a single procedure (bronchoscopy), a maximum of 1 minute after each drug application.Percentage (%) of iatrogenic bronchial bleeding successfully controlled in each group in relation to the severity of the bleeding. Bronchoscopic physicians assess using a Visual Analog Scale (VAS) 1-10 (1 very mild - 10 very severe)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026